Novo partners with Orbis, deepening investment in oral peptide drugs
The potentially $1.4 billion alliance will see the two companies collaborate on “macrocycles” that could yield oral treatments for cardiometabolic diseases.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.